Business Context and Reporting Period
This Form 8-K is a current report filed by Keros Therapeutics, Inc. on February 17, 2021. The company is a Delaware corporation with its principal executive offices in Lexington, Massachusetts. It is classified as an emerging growth company and its common stock trades on The Nasdaq Stock Market LLC under the symbol KROS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event rather than a financial statement.
Material Changes
There are no material financial changes reported in this document. The filing serves to disclose a scheduled corporate presentation.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: The company announced that Jasbir Seehra, President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference.
- Event Details: The presentation is scheduled for Wednesday, February 24, 2021, at 1:40 pm ET.
- Legal Status: The information furnished in this report and the accompanying press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the SVB Leerink Global Healthcare Conference presentation (February 24, 2021, 1:40 pm ET).
- Review the full text of the press release attached as Exhibit 99.1 for specific details on the presentation content.
- Confirm the company's status as an emerging growth company and its listing on Nasdaq under the symbol KROS.
- Note that this 8-K does not contain updated financial data; refer to the most recent 10-K or 10-Q for financial metrics.